Return to search

Adverse pregnancy outcomes among HIV-positive pregnant women treated with efavirenz-containing antiretroviral drugs: a retrospective cohort study in the Cape Flats

Doctor Pharmaceuticae - Dpharm / The use of efavirenz (EFV) in the first trimester of pregnancy
remains controversial. In South Africa, the use of EFV-containing antiretroviral
therapy (ART) as part of a Fixed Dose Combination (FDC) during the first
trimester of pregnancy started in April, 2013. Literature to date has reported
conflicting outcomes following the use of EFV-containing ART during the first
trimester of pregnancy. The objectives of the study were to determine the
prevalence of adverse pregnancy outcomes among HIV-positive pregnant women
treated with EFV-containing ART and compare these results with those of pregnant
women treated with NVP-containing ART and HIV-negative pregnant women in
resource-limited settings. In addition, the study also aimed to determine the effect
of the time of initiation of ART on the prevalence of adverse pregnancy outcomes.

Identiferoai:union.ndltd.org:netd.ac.za/oai:union.ndltd.org:uwc/oai:etd.uwc.ac.za:11394/6185
Date January 2017
CreatorsMohammednur, Mohammedmekin Mohammedseid
ContributorsMugabo, Pierre
PublisherUniversity of the Western Cape
Source SetsSouth African National ETD Portal
LanguageEnglish
Detected LanguageEnglish
TypeThesis
RightsUniversity of the Western Cape

Page generated in 0.0018 seconds